{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:26:34Z","timestamp":1785907594724,"version":"3.56.0"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40120-026-00901-7","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T06:37:09Z","timestamp":1773902229000},"page":"887-906","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["International Expert Opinion on Optimal Switching to Cladribine Tablets from Other High-Efficacy Disease-Modifying Therapies for Relapsing\u2013Remitting Multiple Sclerosis: Opportunities and Challenges"],"prefix":"10.1007","volume":"15","author":[{"given":"Andrew","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raed","family":"Alroughani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Kubala","family":"Havrdov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Z.","family":"Obeidat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Schmierer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Bek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Savarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Korich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Bonsignore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"de Seze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"issue":"6","key":"901_CR1","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.clinthera.2018.04.019","volume":"40","author":"J Visaria","year":"2018","unstructured":"Visaria J, Thomas N, Gu T, Singer J, Tan H. Understanding the patient\u2019s journey in the diagnosis and treatment of multiple sclerosis in clinical practice. Clin Ther. 2018;40(6):926\u201339.","journal-title":"Clin Ther"},{"issue":"7","key":"901_CR2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16289","volume":"31","author":"EC Tallantyre","year":"2024","unstructured":"Tallantyre EC, Dobson R, Froud JLJ, et al. Real-world persistence of multiple sclerosis disease-modifying therapies. Eur J Neurol. 2024;31(7):e16289.","journal-title":"Eur J Neurol"},{"key":"901_CR3","doi-asserted-by":"publisher","first-page":"1274194","DOI":"10.3389\/fneur.2023.1274194","volume":"14","author":"T Spelman","year":"2023","unstructured":"Spelman T, Magyari M, Butzkueven H, et al. Predictors of treatment switching in the Big Multiple Sclerosis Data Network. Front Neurol. 2023;14:1274194.","journal-title":"Front Neurol"},{"issue":"3","key":"901_CR4","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s40120-025-00726-w","volume":"14","author":"P Vermersch","year":"2025","unstructured":"Vermersch P, Moisset X, Roux B, et al. Long-term management and therapeutic sequencing for patients with relapsing multiple sclerosis in France: A Vignette Study. Neurol Ther. 2025;14(3):813\u201327.","journal-title":"Neurol Ther"},{"key":"901_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.647811","volume":"12","author":"J Hillert","year":"2021","unstructured":"Hillert J, Magyari M, Soelberg S\u00f8rensen P, et al. Treatment switching and discontinuation over 20 years in the Big Multiple Sclerosis Data Network. Front Neurol. 2021;12:647811.","journal-title":"Front Neurol"},{"issue":"4","key":"901_CR6","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/S1474-4422(22)00426-4","volume":"22","author":"KM Krysko","year":"2023","unstructured":"Krysko KM, Dobson R, Alroughani R, et al. Family planning considerations in people with multiple sclerosis. Lancet Neurol. 2023;22(4):350\u201366.","journal-title":"Lancet Neurol"},{"issue":"2","key":"901_CR7","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s40120-020-00201-8","volume":"9","author":"R Alroughani","year":"2020","unstructured":"Alroughani R, Inshasi J, Al-Asmi A, et al. Disease-modifying drugs and family planning in people with multiple sclerosis: a consensus narrative review from the Gulf region. Neurol Ther. 2020;9(2):265\u201380.","journal-title":"Neurol Ther"},{"key":"901_CR8","first-page":"205521731560072","volume":"1","author":"C Donz\u00e9","year":"2015","unstructured":"Donz\u00e9 C, Malapel L, Kwiatkowski A, et al. Treatment discontinuation in multiple sclerosis: The French Web-based survey ALLIANCE. Mult Scler J Exp Transl Clin. 2015;1:2055217315600720.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"901_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103857","volume":"63","author":"R Bawand","year":"2022","unstructured":"Bawand R, Ghiasian M, Fathoallahi N, Moradi A. Effects of disease-modifying treatments discontinuation in patients with relapsing-remitting multiple sclerosis: a 5 year prospective cohort study. Mult Scler Relat Disord. 2022;63:103857.","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"901_CR10","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1111\/hex.13109","volume":"23","author":"J P\u00e9trin","year":"2020","unstructured":"P\u00e9trin J, Donnelly C, McColl MA, Finlayson M. Is it worth it?: The experiences of persons with multiple sclerosis as they access health care to manage their condition. Health Expect. 2020;23(5):1269\u201379.","journal-title":"Health Expect"},{"issue":"6","key":"901_CR11","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.1007\/s00415-024-12305-4","volume":"271","author":"BA Singer","year":"2024","unstructured":"Singer BA, Feng J, Chiong-Rivero H. Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption. J Neurol. 2024;271(6):3116\u201330.","journal-title":"J Neurol"},{"issue":"3","key":"901_CR12","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/WCO.0000000000000937","volume":"34","author":"K Schmierer","year":"2021","unstructured":"Schmierer K, S\u00f8rensen PS, Baker D. Highly effective disease-modifying treatment as initial RMS therapy. Curr Opin Neurol. 2021;34(3):286\u201394.","journal-title":"Curr Opin Neurol"},{"issue":"4","key":"901_CR13","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2217\/nmt-2020-0016","volume":"10","author":"JS Inshasi","year":"2020","unstructured":"Inshasi JS, Almadani A, Fahad SA, et al. High-efficacy therapies for relapsing-remitting multiple sclerosis: implications for adherence. An expert opinion from the United Arab Emirates. Neurodegener Dis Manag. 2020;10(4):257\u201366.","journal-title":"Neurodegener Dis Manag"},{"issue":"1","key":"901_CR14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s40120-020-00187-3","volume":"9","author":"IA AlSharoqi","year":"2020","unstructured":"AlSharoqi IA, Aljumah M, Bohlega S, et al. Immune reconstitution therapy or continuous immunosuppression for the management of active relapsing-remitting multiple sclerosis patients? a narrative review. Neurol Ther. 2020;9(1):55\u201366.","journal-title":"Neurol Ther"},{"issue":"2","key":"901_CR15","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s40120-022-00339-7","volume":"11","author":"G Giovannoni","year":"2022","unstructured":"Giovannoni G, Mathews J. Cladribine tablets for relapsing-remitting multiple sclerosis: a clinician\u2019s review. Neurol Ther. 2022;11(2):571\u201395.","journal-title":"Neurol Ther"},{"key":"901_CR16","doi-asserted-by":"publisher","DOI":"10.1177\/17562864251351760","author":"K Schmierer","year":"2025","unstructured":"Schmierer K, Wiendl H, Barkhof F, et al. Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS study. Ther Adv Neurol Disord. 2025. https:\/\/doi.org\/10.1177\/17562864251351760.","journal-title":"Ther Adv Neurol Disord"},{"key":"901_CR17","doi-asserted-by":"publisher","first-page":"1512189","DOI":"10.3389\/fimmu.2025.1512189","volume":"16","author":"H Wiendl","year":"2025","unstructured":"Wiendl H, Barkhof F, Montalban X, et al. Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study. Front Immunol. 2025;16:1512189.","journal-title":"Front Immunol"},{"key":"901_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.106107","volume":"92","author":"T Leist","year":"2024","unstructured":"Leist T, Yamout Y, Harlow D, Javor A. Post-approval safety of cladribine tablets in the treatment of patients with multiple sclerosis: 2024 update. Mult Scler Relat Disord. 2024;92:106107 (abstract).","journal-title":"Mult Scler Relat Disord"},{"key":"901_CR19","doi-asserted-by":"crossref","unstructured":"Clavelou P, Castelnovo G, Pourcher V, et al. Expert narrative review of the safety of cladribine tablets for the management of relapsing multiple sclerosis [published correction appears in Neurol Ther. 2024;13(1):255\u2013256.","DOI":"10.1007\/s40120-023-00564-8"},{"issue":"5","key":"901_CR20","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s40120-024-00650-5","volume":"13","author":"B Yamout","year":"2024","unstructured":"Yamout B, Alroughani R, Inshasi J, et al. Practical recommendations from the Gulf region on the therapeutic use of cladribine tablets for the management of relapsing multiple sclerosis: impact of the latest real-world evidence on clinical practice. Neurol Ther. 2024;13(5):1321\u201335.","journal-title":"Neurol Ther"},{"issue":"3","key":"901_CR21","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s40120-024-00603-y","volume":"13","author":"J de Seze","year":"2024","unstructured":"de Seze J, Dive D, Ayrignac X, et al. Narrative review on the use of cladribine tablets as exit therapy for stable elderly patients with multiple sclerosis. Neurol Ther. 2024;13(3):519\u201333.","journal-title":"Neurol Ther"},{"issue":"3","key":"901_CR22","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s40120-024-00589-7","volume":"13","author":"J Ciron","year":"2024","unstructured":"Ciron J, Bourre B, Castelnovo G, et al. Holistic, long-term management of people with relapsing multiple sclerosis with cladribine tablets: expert opinion from France. Neurol Ther. 2024;13(3):503\u201318.","journal-title":"Neurol Ther"},{"key":"901_CR23","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa0902533","volume":"362","author":"G Giovannoni","year":"2010","unstructured":"Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362:416\u201326.","journal-title":"N Engl J Med"},{"issue":"12","key":"901_CR24","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1177\/1352458517727603","volume":"24","author":"G Giovannoni","year":"2018","unstructured":"Giovannoni G, Soelberg Sorensen P, Cook S, et al. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Mult Scler. 2018;24(12):1594\u2013604.","journal-title":"Mult Scler"},{"key":"901_CR25","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1177\/13524585231161494","volume":"29","author":"G Giovannoni","year":"2023","unstructured":"Giovannoni G, Boyko A, Correale J, et al. Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY\/CLARITY Extension cohort of CLASSIC-MS: an ambispective study. Mult Scler J. 2023;29:719\u201330.","journal-title":"Mult Scler J"},{"key":"901_CR26","doi-asserted-by":"crossref","unstructured":"Kleinschnitz C, Skuljec J, Kowarik MC, et al. First insights into the safety and effectiveness of additional courses with cladribine tablets under real-world conditions. Mult Scler Relat Disord. 2025:97:106398.","DOI":"10.1016\/j.msard.2025.106398"},{"key":"901_CR27","volume":"69","author":"C Oreja-Guevara","year":"2023","unstructured":"Oreja-Guevara C, Brownlee W, Celius EG, et al. Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: systematic literature review of real-world evidence. Mult Scler J. 2023;69:104459.","journal-title":"Mult Scler J"},{"issue":"4","key":"901_CR28","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200415","volume":"12","author":"T Guerra","year":"2025","unstructured":"Guerra T, Copetti M, Zanetta C, et al. The Italian multiple sclerosis register experience with cladribine: impact on relapses, PIRA, and treatment sequencing strategies evaluation. Neurol Neuroimmunol Neuroinflamm. 2025;12(4):e200415.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"901_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106724","volume":"103","author":"I Rauma","year":"2025","unstructured":"Rauma I, Viitala M, Soilu-H\u00e4nninen M, et al. The real-world efficacy of Cladribine tablets and treatment persistence in people with highly active relapsing multiple sclerosis in Finland\u2014a follow-up study after four years of observation. Mult Scler Relat Disord. 2025;103:106724.","journal-title":"Mult Scler Relat Disord"},{"key":"901_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106272","volume":"94","author":"DS Conway","year":"2025","unstructured":"Conway DS, Nicholas JA, Thompson NR, Mowry EM, Naismith RT. Real world experience with cladribine tablets for multiple sclerosis at four academic multiple sclerosis centers. Mult Scler Relat Disord. 2025;94:106272.","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"901_CR31","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/WNF.0000000000000598","volume":"47","author":"JI Rojas","year":"2024","unstructured":"Rojas JI, Alonso R, Luetic G, et al. Real-world effectiveness and safety of Cladribine in Multiple Sclerosis: longitudinal data from the nationwide registry in Argentina. Clin Neuropharmacol. 2024;47(4):120\u20137.","journal-title":"Clin Neuropharmacol"},{"key":"901_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105704","volume":"88","author":"MC Kowarik","year":"2024","unstructured":"Kowarik MC, Ernst M, Woitschach L, et al. Real-world therapy management of patients with multiple sclerosis receiving cladribine tablets beyond year 4\u2014results from a German cladribine cohort. Mult Scler Relat Disord. 2024;88:105704.","journal-title":"Mult Scler Relat Disord"},{"issue":"9","key":"901_CR33","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1177\/13524585241267211","volume":"30","author":"I Roos","year":"2024","unstructured":"Roos I, Sharmin S, Malpas C, et al. Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis. Mult Scler. 2024;30(9):1163\u201375.","journal-title":"Mult Scler"},{"key":"901_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103931","volume":"64","author":"L Rolfes","year":"2022","unstructured":"Rolfes L, Pfeuffer S, Huntemann N, et al. Immunological consequences of cladribine treatment in multiple sclerosis: a real-world study. Mult Scler Relat Disord. 2022;64:103931.","journal-title":"Mult Scler Relat Disord"},{"key":"901_CR35","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.msard.2019.02.018","volume":"30","author":"D Baker","year":"2019","unstructured":"Baker D, Pryce G, Herrod SS, Schmierer K. Potential mechanisms of action related to the efficacy and safety of cladribine. Mult Scler Relat Disord. 2019;30:176\u201386.","journal-title":"Mult Scler Relat Disord"},{"key":"901_CR36","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ebiom.2017.01.042","volume":"16","author":"D Baker","year":"2017","unstructured":"Baker D, Marta M, Pryce G, Giovannoni G, Schmierer K. Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis. EBioMedicine. 2017;16:41\u201350.","journal-title":"EBioMedicine"},{"key":"901_CR37","doi-asserted-by":"crossref","unstructured":"Wiendl H, de Stefano N, Vermersch P, et al. Durable impact of immune cell reconstitution over 4 years following short course cladribine tablets: results from MAGNIFY-MS Extension Study. Mult Scler J. 2025:31(2 Suppl):92 (abstract).","DOI":"10.1016\/j.msard.2024.106123"},{"key":"901_CR38","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.msard.2019.01.038","volume":"29","author":"G Comi","year":"2019","unstructured":"Comi G, Cook S, Giovannoni G, et al. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. Mult Scler Relat Disord. 2019;29:168\u201374.","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"901_CR39","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s40262-018-0693-y","volume":"58","author":"N Terranova","year":"2019","unstructured":"Terranova N, Hicking C, Dangond F, Munafo A. Effects of postponing treatment in the second year of cladribine administration: clinical trial simulation analysis of absolute lymphocyte counts and relapse rate in patients with relapsing-remitting multiple sclerosis. Clin Pharmacokinet. 2019;58(3):325\u201333.","journal-title":"Clin Pharmacokinet"},{"issue":"3S","key":"901_CR40","first-page":"997","volume":"29","author":"D O'Neill","year":"2023","unstructured":"O\u2019Neill D, Hodgkinson S, Dong G, Sharma M. The Sydney Cladribine Cohort: five year data. Mult Scler J. 2023;29(3S):997 (Abstract).","journal-title":"Mult Scler J"},{"key":"901_CR41","doi-asserted-by":"crossref","unstructured":"Cook S, Comi G, Giovannoni G, et al. Rates of lymphopenia in years 1\u20134 in patients with relapsing multiple sclerosis treated annually with cladribine tablets. Abstract 039 presented at the Australian & New Zealand Association of Neurologists (ANZAN) meeting, May 29th\u2013June 1st 2018, Darwin, Australia. https:\/\/jnnp.bmj.com\/content\/89\/6\/A16.2. Accessed Jan 2026.","DOI":"10.1136\/jnnp-2018-ANZAN.38"},{"issue":"2","key":"901_CR42","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1177\/13524585211012227","volume":"28","author":"S Pfeuffer","year":"2022","unstructured":"Pfeuffer S, Rolfes L, Hackert J, et al. Effectiveness and safety of cladribine in RMS: real-world experience from two tertiary centres. Mult Scler. 2022;28(2):257\u201368.","journal-title":"Mult Scler"},{"key":"901_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102572","volume":"46","author":"T Leist","year":"2020","unstructured":"Leist T, Cook S, Comi G, et al. Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis. Mult Scler Relat Disord. 2020;46:102572.","journal-title":"Mult Scler Relat Disord"},{"issue":"10","key":"901_CR44","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.2174\/1570159X20666211217160451","volume":"20","author":"L Moiola","year":"2022","unstructured":"Moiola L, Riva A, Nicoletti F, et al. Vaccination opportunities in multiple sclerosis patients treated with cladribine tablets. Curr Neuropharmacol. 2022;20(10):1811\u20135.","journal-title":"Curr Neuropharmacol"},{"issue":"13","key":"901_CR45","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1177\/13524585221099413","volume":"28","author":"K Schmierer","year":"2022","unstructured":"Schmierer K, Wiendl H, Oreja-Guevara C, et al. Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis. Mult Scler. 2022;28(13):2151\u20133.","journal-title":"Mult Scler"},{"issue":"6","key":"901_CR46","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1007\/s10072-025-08018-9","volume":"46","author":"MWY Leung","year":"2025","unstructured":"Leung MWY, Garde EMWV, Uitdehaag BMJ, Klungel OH, Bazelier MT. The relative risk of infection in people with multiple sclerosis using disease-modifying treatment: a systematic review of observational studies. Neurol Sci. 2025;46(6):2555\u201369.","journal-title":"Neurol Sci"},{"key":"901_CR47","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000158","volume":"2","author":"J Pakpoor","year":"2015","unstructured":"Pakpoor J, Disanto G, Altmann DR, Pavitt S, Turner BP, Marta M, et al. No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine. Neurol Neuroimmunol Neuroinflamm. 2015;2:e158.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"901_CR48","unstructured":"European Medicines Agency. Mavenclad. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mavenclad. Accessed Jan 2026."},{"key":"901_CR49","unstructured":"EMD Serono. Mavenclad\u00ae US Prescribing Information. https:\/\/www.emdserono.com\/content\/dam\/web\/corporate\/non-images\/country-specifics\/us\/pi\/mavenclad-pi.pdf. Accessed Jan 2026."},{"issue":"17","key":"901_CR50","doi-asserted-by":"publisher","first-page":"e1926","DOI":"10.1212\/WNL.0000000000201029","volume":"99","author":"I Roos","year":"2022","unstructured":"Roos I, Malpas C, Leray E, et al. Disease reactivation after cessation of disease-modifying therapy in patients with relapsing-remitting multiple sclerosis. Neurology. 2022;99(17):e1926\u201344.","journal-title":"Neurology"},{"key":"901_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103076","volume":"53","author":"K Bigaut","year":"2021","unstructured":"Bigaut K, Cohen M, Durand-Dubief F, et al. How to switch disease-modifying treatments in multiple sclerosis: guidelines from the French Multiple Sclerosis Society (SFSEP). Mult Scler Relat Disord. 2021;53:103076.","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"901_CR52","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1017\/cjn.2015.325","volume":"43","author":"Y Lapierre","year":"2016","unstructured":"Lapierre Y, O\u2019Connor P, Devonshire V, Freedman RMS, Kremenchutzky M, Yeung M, et al. Canadian experience with fingolimod: adherence to treatment and monitoring. Can J Neurol Sci. 2016;43(2):278\u201383.","journal-title":"Can J Neurol Sci"},{"issue":"3","key":"901_CR53","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000548","volume":"6","author":"T Ziemssen","year":"2019","unstructured":"Ziemssen T, Lang M, Tackenberg B, et al. Real-world persistence and benefit-risk profile of fingolimod over 36 months in Germany. Neurol Neuroimmunol Neuroinflamm. 2019;6(3):e548.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"901_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.611711","volume":"12","author":"Z Zhao","year":"2021","unstructured":"Zhao Z, Ma CL, Gu ZC, Dong Y, Lv Y, Zhong MK. Incidence and risk of infection associated with Fingolimod in patients with multiple sclerosis: a systematic review and meta-analysis of 8,448 patients from 12 randomized controlled trials. Front Immunol. 2021;12:611711.","journal-title":"Front Immunol"},{"issue":"2","key":"901_CR55","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1177\/13524585221137502","volume":"29","author":"T Spelman","year":"2023","unstructured":"Spelman T, Ozakbas S, Alroughani R, et al. Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: results from RMSBase registry. Mult Scler. 2023;29(2):221\u201335.","journal-title":"Mult Scler"},{"issue":"3","key":"901_CR56","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1007\/s13311-021-01102-w","volume":"18","author":"HP Hartung","year":"2021","unstructured":"Hartung HP, Mares J, Meuth SG, Berger T. Multiple sclerosis: switching from natalizumab to other high-efficacy treatments to mitigate progressive multifocal leukoencephalopathy risk. Neurotherapeutics. 2021;18(3):1654\u20136.","journal-title":"Neurotherapeutics"},{"key":"901_CR57","doi-asserted-by":"publisher","first-page":"175628642412338","DOI":"10.1177\/17562864241233858","volume":"17","author":"PV Sguigna","year":"2024","unstructured":"Sguigna PV, Hussain RZ, Okai A, et al. Cladribine tablets after treatment with natalizumab (CLADRINA)\u2014rationale and design. Ther Adv Neurol Disord. 2024;17:17562864241233858.","journal-title":"Ther Adv Neurol Disord"},{"key":"901_CR58","unstructured":"Sguigna P, Okai A, Kaplan J, et al. Two-year findings on the safety and efficacy of cladribine tablets after treatment with natalizumab (CLADRINA Trial). Abstract\/poster P147 at the 1oth ACTRIMS Forum, West Palm Beach, Florida, USA, February 27\u2212March 1, 2025."},{"key":"901_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109688","volume":"253","author":"T Chitnis","year":"2023","unstructured":"Chitnis T, Foley J, Ionete C, et al. Clinical validation of a multi-protein, serum-based assay for disease activity assessments in multiple sclerosis. Clin Immunol. 2023;253:109688.","journal-title":"Clin Immunol"},{"key":"901_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.105134","volume":"81","author":"A Maunula","year":"2024","unstructured":"Maunula A, Atula S, Laakso SM, Tienari PJ. Frequency and risk factors of rebound after fingolimod discontinuation\u2014a retrospective study. Mult Scler Relat Disord. 2024;81:105134.","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"901_CR61","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1177\/19418744211031360","volume":"12","author":"JD Lee","year":"2022","unstructured":"Lee JD, Chen T. Natalizumab rebound in multiple sclerosis. Neurohospitalist. 2022;12(1):197\u20138.","journal-title":"Neurohospitalist"},{"key":"901_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1380654","volume":"15","author":"A Elgenidy","year":"2024","unstructured":"Elgenidy A, Abdelhalim NN, Al-Kurdi MA, et al. Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 treatments: a systematic review and meta-analysis of 19,139 multiple sclerosis patients. Front Neurol. 2024;15:1380654.","journal-title":"Front Neurol"},{"key":"901_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.106191","volume":"93","author":"K Smolik","year":"2025","unstructured":"Smolik K, Camilli F, Panzera I, et al. Hypogammaglobulinemia and severe infections in Multiple Sclerosis patients on anti-CD20 agents: a multicentre study. Mult Scler Relat Disord. 2025;93:106191.","journal-title":"Mult Scler Relat Disord"},{"key":"901_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103418","volume":"57","author":"I Smets","year":"2022","unstructured":"Smets I, Giovannoni G. Derisking CD20-therapies for long-term use. Mult Scler Relat Disord. 2022;57:103418.","journal-title":"Mult Scler Relat Disord"},{"key":"901_CR65","doi-asserted-by":"publisher","first-page":"175628642110128","DOI":"10.1177\/17562864211012835","volume":"14","author":"A Achiron","year":"2021","unstructured":"Achiron A, Mandel M, Dreyer-Alster S, et al. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord. 2021;14:17562864211012836.","journal-title":"Ther Adv Neurol Disord"},{"issue":"14","key":"901_CR66","doi-asserted-by":"publisher","first-page":"e1999","DOI":"10.1212\/WNL.0000000000010380","volume":"95","author":"A Bar-Or","year":"2020","unstructured":"Bar-Or A, Calkwood JC, Chognot C, et al. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study. Neurology. 2020;95(14):e1999\u20132008.","journal-title":"Neurology"},{"issue":"5","key":"901_CR67","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1177\/13524585211055593","volume":"28","author":"L Rolfes","year":"2022","unstructured":"Rolfes L, Meuth SG. Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing-\"Yes\". Mult Scler. 2022;28(5):691\u20133.","journal-title":"Mult Scler"},{"key":"901_CR68","doi-asserted-by":"publisher","DOI":"10.1177\/13524585251329849","author":"L Revie","year":"2025","unstructured":"Revie L, J\u00fcrjens A, Eveslage M, et al. Suboptimal B-cell depletion is associated with progression independent of relapse activity in multiple sclerosis patients treated with ocrelizumab. Mult Scler. 2025;31:813-820.","journal-title":"Mult Scler"},{"issue":"2S","key":"901_CR69","first-page":"211","volume":"31","author":"G Pardo","year":"2025","unstructured":"Pardo G, Berkley C, Sharp A, Smith J, Drake M, Fjeldstad Pardo C. Cladribine tablets real world clinical and safety outcomes in a large relapsing multiple sclerosis cohort. Mult Scler J. 2025;31(2S):211 (Abstract).","journal-title":"Mult Scler J"},{"key":"901_CR70","unstructured":"Dukkipati R et al. Efficacy and safety of cladribine tablets in a large, real-world, MULTICENTER United States Population. Abstract Nr. LBA06. Presented at CMSC 2025, 28\u201331 May 2025, Phoenix, Arizona."},{"issue":"3S","key":"901_CR71","first-page":"1007","volume":"29","author":"D O'Neill","year":"2023","unstructured":"O\u2019Neill D, Hodgkinson S, Dong G, Sharma S. Transitioning from ocrelizumab to cladribine: real world evidence. Mult Scler J. 2023;29(3S):1007 (Abstract).","journal-title":"Mult Scler J"},{"key":"901_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.106145","volume":"92","author":"R Sacco","year":"2024","unstructured":"Sacco R, Disanto G, Pravat\u00e0 E, et al. De-escalation from anti-CD20 to cladribine tablets in multiple sclerosis: a pilot study. Mult Scler Relat Disord. 2024;92:106145.","journal-title":"Mult Scler Relat Disord"},{"key":"901_CR73","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1177\/13524585251324850","volume":"31","author":"G Pardo","year":"2025","unstructured":"Pardo G, Berkley C, Sharp A, Smith J, Drake M, Pardo CF. Cladribine tablets real-world clinical and safety outcomes in a relapsing multiple sclerosis cohort including older individuals and transitioning from an anti-CD20. Mult Scler J. 2025;31:1243 (Abstract).","journal-title":"Mult Scler J"},{"key":"901_CR74","doi-asserted-by":"crossref","unstructured":"Konen FF, Pfeuffer S, Jendretzky KF, et al. Switching from anti-CD20 therapies to cladribine and vice versa - Analysis of a German relapsing multiple sclerosis cohort. Neurotherapeutics. 2025; Dec 3:e00812.","DOI":"10.1016\/j.neurot.2025.e00812"},{"key":"901_CR75","unstructured":"Sacco R, Disanto G, Mallucci, G, et al. Long-term follow-up of multiple sclerosis patients treated with cladribine tablets as de-escalation strategy from anti-CD20. Mult Scler J Mult Scler J. 2025;31:1178 (Abstract)."},{"issue":"6","key":"901_CR76","doi-asserted-by":"publisher","first-page":"480","DOI":"10.5603\/PJNNS.a2022.0068","volume":"56","author":"K Piasecka-Stryczy\u0144ska","year":"2022","unstructured":"Piasecka-Stryczy\u0144ska K, Kaczy\u0144ski \u0141, Rolka M, et al. Systematic review and network meta-analysis (NMA) for cladribine tablets in achieving sustained disability improvement (SDI) in multiple sclerosis. Neurol Neurochir Pol. 2022;56(6):480\u20139.","journal-title":"Neurol Neurochir Pol"},{"key":"901_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102769","volume":"49","author":"H Bartosik-Psujek","year":"2021","unstructured":"Bartosik-Psujek H, Kaczy\u0144ski \u0141, G\u00f3recka M, et al. Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis\u2014a systematic review and network meta-analysis. Mult Scler Relat Disord. 2021;49:102769.","journal-title":"Mult Scler Relat Disord"},{"issue":"14","key":"901_CR78","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1212\/01.wnl.0000277457.17420.b5","volume":"69","author":"PA Calabresi","year":"2007","unstructured":"Calabresi PA, Giovannoni G, Confavreux C, et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology. 2007;69(14):1391\u2013403.","journal-title":"Neurology"},{"key":"901_CR79","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1177\/13524585211010294","volume":"28","author":"N De Stefano","year":"2022","unstructured":"De Stefano N, Sormani MP, Giovannoni G, et al. Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies. Mult Scler. 2022;28:111\u201320.","journal-title":"Mult Scler"},{"issue":"4","key":"901_CR80","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001187","volume":"9","author":"N de Stefano","year":"2022","unstructured":"de Stefano N, Barkhof F, Montalban X, et al. Early Reduction of MRI Activity during 6 months of treatment with cladribine tablets for highly active relapsing multiple sclerosis: MAGNIFY-MS. Neurol Neuroimmunol Neuroinflamm. 2022;9(4):e1187.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"901_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.105335","volume":"80","author":"J Inshasi","year":"2023","unstructured":"Inshasi J, Alroughani R, Al Shamali SA, Shatila A, Szolics M, Benedetti B. Rebound of multiple sclerosis disease activity after switching from fingolimod or natalizumab to cladribine tablets: real world experience from the Arabian Gulf. Mult Scler Relat Disord. 2023;80:105335 (Abstract).","journal-title":"Mult Scler Relat Disord"},{"key":"901_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103812","volume":"62","author":"GO Nygaard","year":"2022","unstructured":"Nygaard GO, Torgauten H, Skatteb\u00f8l L, H\u00f8gest\u00f8l EA, Sowa P, Myhr KM, et al. Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis. Mult Scler Relat Disord. 2022;62:103812.","journal-title":"Mult Scler Relat Disord"},{"key":"901_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.101938","volume":"40","author":"F Coss-Rovirosa","year":"2020","unstructured":"Coss-Rovirosa F, Salado-Burbano J, Casallas-Vanegas A, Caire-Herrera LE, G\u00f3mez-Figueroa E, Flores-Rivera J. Severe fingolimod rebound syndrome after switching to cladribine treatment. Mult Scler Relat Disord. 2020;40:101938.","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"901_CR84","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/acn3.52017","volume":"11","author":"PK Coyle","year":"2024","unstructured":"Coyle PK, Freedman RMS, Cohen BA, Cree BAC, Markowitz CE. Sphingosine 1-phosphate receptor modulators in multiple sclerosis treatment: a practical review. Ann Clin Transl Neurol. 2024;11(4):842\u201355.","journal-title":"Ann Clin Transl Neurol"},{"issue":"16","key":"901_CR85","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1007\/s40265-017-0814-1","volume":"77","author":"G Comi","year":"2017","unstructured":"Comi G, Hartung HP, Bakshi R, Williams IM, Wiendl H. Benefit-risk profile of sphingosine-1-phosphate receptor modulators in relapsing and secondary progressive multiple sclerosis. Drugs. 2017;77(16):1755\u201368.","journal-title":"Drugs"},{"key":"901_CR86","unstructured":"Babaesfahani A, Khanna NR, Patel P, Kuns B. Natalizumab. Stat Pearls [Internet]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK534201\/. Accessed Jan 2026."},{"key":"901_CR87","unstructured":"Maynard M, Bass JA, Salter A, et al. Prior disease-modifying therapy influence on lymphocyte dynamics after treatment with oral cladribine in multiple sclerosis. Mult Scler J 2024;30 (1S):98 (Abstract)."},{"key":"901_CR88","unstructured":"Rocha Cabrero F, Morrison EH. Cladribine. Stat Pearls [Internet], March 20 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK545307\/. Accessed Jan 2026."},{"issue":"2","key":"901_CR89","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/WNF.0b013e3181cbf825","volume":"33","author":"J Chun","year":"2010","unstructured":"Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010;33(2):91\u2013101.","journal-title":"Clin Neuropharmacol"},{"issue":"5","key":"901_CR90","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1097\/GCO.0000000000000731","volume":"33","author":"G Varyt\u0117","year":"2021","unstructured":"Varyt\u0117 G, Arlauskien\u0117 A, Rama\u0161auskait\u0117 D. Pregnancy and multiple sclerosis: an update. Curr Opin Obstet Gynecol. 2021;33(5):378\u201383.","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"2","key":"901_CR91","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1136\/practneurol-2018-002060","volume":"19","author":"R Dobson","year":"2019","unstructured":"Dobson R, Dassan P, Roberts M, Giovannoni G, Nelson-Piercy C, Brex PA. UK consensus on pregnancy in multiple sclerosis: \u201cAssociation of British Neurologists\u201d guidelines. Pract Neurol. 2019;19(2):106\u201314.","journal-title":"Pract Neurol"},{"key":"901_CR92","volume":"2021","author":"M Al Jumah","year":"2021","unstructured":"Al Jumah M, Al Malik Y, AlKhawajah NM, et al. Family planning for people with multiple sclerosis in Saudi Arabia: an expert consensus. Mult Scler Int. 2021;2021:6667006.","journal-title":"Mult Scler Int"},{"key":"901_CR93","unstructured":"European Medicines Agency. Ocrevus. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ocrevus. Accessed Jan 2026."},{"issue":"7","key":"901_CR94","doi-asserted-by":"publisher","first-page":"4039","DOI":"10.1007\/s00415-024-12291-7","volume":"271","author":"E Signoriello","year":"2024","unstructured":"Signoriello E, Foschi M, Lanzillo R, et al. Pregnancy effect on disease activity in women with multiple sclerosis treated with cladribine. J Neurol. 2024;271(7):4039\u201345.","journal-title":"J Neurol"},{"key":"901_CR95","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1001\/jamaneurol.2023.1135","volume":"80","author":"M Hittle","year":"2023","unstructured":"Hittle M, Culpepper WJ, Langer-Gould A, et al. Population-based estimates for the prevalence of multiple sclerosis in the United States by race, ethnicity, age, sex, and geographic region. JAMA Neurol. 2023;80:693\u2013701.","journal-title":"JAMA Neurol"},{"key":"901_CR96","doi-asserted-by":"crossref","unstructured":"Wallin MT, Culpepper WJ, Campbell JD, et al. The prevalence of RMS in the United States: a population-based estimate using health claims data [published correction appears in Neurology. 2019;93(15):688.","DOI":"10.1212\/WNL.0000000000007915"},{"key":"901_CR97","unstructured":"Public Health England. Research and analysis. Multiple sclerosis: prevalence, incidence and smoking status\u2014data briefing. Published 4 February 2020. https:\/\/www.gov.uk\/government\/publications\/multiple-sclerosis-prevalence-incidence-and-smoking-status\/multiple-sclerosis-prevalence-incidence-and-smoking-status-data-briefing. Accessed Jan 2026."},{"key":"901_CR98","doi-asserted-by":"publisher","first-page":"1234572","DOI":"10.3389\/fragi.2023.1234572","volume":"4","author":"S Thakolwiboon","year":"2023","unstructured":"Thakolwiboon S, Mills EA, Yang J, et al. Immunosenescence and multiple sclerosis: inflammaging for prognosis and therapeutic consideration. Front Aging. 2023;4:1234572.","journal-title":"Front Aging"},{"issue":"7","key":"901_CR99","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-020-01046-2","volume":"20","author":"B Zeydan","year":"2020","unstructured":"Zeydan B, Kantarci OH. Impact of age on multiple sclerosis disease activity and progression. Curr Neurol Neurosci Rep. 2020;20(7):24.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"14","key":"901_CR100","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1177\/13524585231199820","volume":"29","author":"SLS Jacober","year":"2023","unstructured":"Jacober SLS, Disanto G, Sacco R, et al. Interplay between age and disease-modifying treatments in influencing infection risk in multiple sclerosis. Mult Scler. 2023;29(14):1765\u201375.","journal-title":"Mult Scler"},{"key":"901_CR101","doi-asserted-by":"crossref","unstructured":"Giovanonni G, Rammohan K, Cook S, et al. Cladribine tablets 35 mg\/kg is efficacious in patients aged above and below 45 years with relapsing multiple sclerosis in the clarity study. Mult Scler Relat Disord. 2018;26:P262 (Abstract).","DOI":"10.1016\/j.msard.2018.10.097"},{"issue":"1","key":"901_CR102","volume":"11","author":"J de Seze","year":"2025","unstructured":"de Seze J, Zecca C, Castelnovo G, et al. European experience of cladribine tablets in elderly patients with multiple sclerosis: could it be the last treatment? Mult Scler J Exp Transl Clin. 2025;11(1):20552173251321810.","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"3S","key":"901_CR103","first-page":"1096","volume":"30","author":"D Negroski","year":"2024","unstructured":"Negroski D. Durable efficacy of cladribine tablets in an aging (> 50 years of age) RMS patient population\u2014a real-world experience. Mult Scler J. 2024;30(3S):1096 (Abstract).","journal-title":"Mult Scler J"},{"key":"901_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2024.123070","volume":"462","author":"A Manni","year":"2024","unstructured":"Manni A, Oggiano F, Palazzo C, et al. Clinical and biological predictors of cladribine effectiveness in multiple sclerosis: a real-world, single centre study considering a two-year interval from year-2 dosing. J Neurol Sci. 2024;462:123070.","journal-title":"J Neurol Sci"},{"key":"901_CR105","unstructured":"Cote J, Goulette P, Walch R, et al. Impact of cladribine tablets on serum neurofilament light chain levels in patients with relapsing multiple sclerosis: results from a us based real-world study. Mult Scler J. 2025;31(2S):43 (Abstract)."},{"key":"901_CR106","unstructured":"Schmierer K, Vermersch P, Wiendl H, et al. Durable effects of cladribine tablets on CSF OCB and NfL Over 4 yYears in relapsing multiple sclerosis: results from the MAGNIFY-MS Extension Study. Mult Scler J. 2025;31(2S):91 (Abstract)."},{"key":"901_CR107","unstructured":"Langdon D, Brochet B, Havrdova EK, et al. Improvements in health-related quality of life and preserved cognitive function in patients with relapsing multiple sclerosis: 4-year results from the CLARIFY-MS Extension Study. Mult Scler J. 2025;31(2S):176 (Abstract)."},{"issue":"7","key":"901_CR108","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/S1474-4422(23)00154-0","volume":"22","author":"JR Corboy","year":"2023","unstructured":"Corboy JR, Fox RJ, Kister I, et al. Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial. Lancet Neurol. 2023;22(7):568\u201377.","journal-title":"Lancet Neurol"},{"issue":"2","key":"901_CR109","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1177\/13524585241303489","volume":"31","author":"JR Corboy","year":"2025","unstructured":"Corboy JR, Fox RJ, Cutter G, et al. DISCOntinuation of disease-modifying therapies in RMS: The DISCOMS extension trial. Mult Scler. 2025;31(2):159\u201373.","journal-title":"Mult Scler"},{"issue":"4","key":"901_CR110","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s40120-025-00767-1","volume":"14","author":"R Alroughani","year":"2025","unstructured":"Alroughani R, Inshasi J, Farouk S, et al. Role of immune reconstitution therapy with cladribine tablets in the management of relapsing multiple sclerosis in older patients. Neurol Ther. 2025;14(4):1169\u201384.","journal-title":"Neurol Ther"},{"key":"901_CR111","unstructured":"Katz J, Hughes B, Gutierrez A, et al. Clinical outcomes of cladribine tablets in aging (\u2265\u00a050 years) patients with relapsing multiple sclerosis in a real-world setting: insights from the \u2018Aging\u2019 Study. Mult Scler J. 2025;31:384 (Abstract)."},{"key":"901_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2025.123727","volume":"478","author":"MA Piedrabuena","year":"2025","unstructured":"Piedrabuena MA, Correale J, Silva B, et al. Efficacy and safety of Cladribine as a therapeutic option in multiple sclerosis patients over 50 years of age: a real-world study. J Neurol Sci. 2025;478:123727.","journal-title":"J Neurol Sci"},{"issue":"1","key":"901_CR113","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s40120-022-00422-z","volume":"12","author":"M Habek","year":"2023","unstructured":"Habek M, Drulovic J, Brecl Jakob G, et al. Treatment with cladribine tablets beyond year 4: a position statement by Southeast European Multiple Sclerosis Centers. Neurol Ther. 2023;12(1):25\u201337.","journal-title":"Neurol Ther"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00901-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00901-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00901-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T15:06:27Z","timestamp":1778684787000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00901-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":113,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["901"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00901-7","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"22 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Andrew Chan received research support from Biogen, CSL Behring, Genzyme, Roche, UCB, SNF and the European Union; received speaker honoraria and fees for consultancy and advisory boards from Argenx, Alexion, Amgen, Biogen, Bristol Myers Squibb, Horizon Therapeutics, Janssen\/J&J, Merck, Novartis, Roche, Sanofi, Sandoz, Teva and UCB. Magnus Andersson received honoraria as a speaker and adviser from Merck and Sanofi. Raed Alroughani received honoraria as a speaker and for serving on scientific advisory boards from Bayer, Biogen, Merck, Novartis, Roche, and Sanofi. Massimiliano Calabrese received speaker honoraria and fees for consultancy and advisory boards from Biogen, Bristol Myers Squibb, Merck Serono, Amgen, Novartis, Sanofi and Roche and received research support from the Progressive RMS Alliance and Italian Minister of Health and Bristol Myers Squibb, Merck Serono, Novartis, and Roche. Eva Kubala Havrdov\u00e1 has received fees for consultancy, advisory board and clinical trials from Novartis, Biogen, Merck, Teva, Genzyme\/ Sanofi, Roche, BMS\/Celgene, Janssen. Ahmed Z. Obeidat has received personal compensation for participation in scientific advisory boards, steering committees, and\/or speaking engagements from Alexion Pharmaceuticals, Amgen, AstraZeneca, Banner Life Sciences, BD Biosciences, Biogen, Biologix Solutions, Bristol Myers Squibb, Celgene, EMD Serono, Genentech, GW Pharmaceuticals, Horizon Therapeutics, Jazz Pharmaceuticals, Merck, Novartis, Roche, Sandoz, Sanofi\/Genzyme, TG Therapeutics, and Viela Bio. Klaus Schmierer has received research support, through Queen Mary University of London, from Biogen, Merck, Novartis, Roche, Sandoz, and Sanofi; speaking honoraria from, and\/or served in an advisory role for, Biogen, EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany, Merck, Neuraxpharm, Novartis, Roche, and Sanofi; and remuneration for teaching activities from AcadeMe and Medscape. Jerome de Seze has received fees for consultancy, advisory board and clinical trials from UCB, Novartis, Biogen, Merck, Teva, Genzyme\/ Sanofi, Roche, Alexion, BMS\/Celegene, Janssen, Horizon Therapeutics. Louise Bek is an employee of Merck Healthcare KGaA, Darmstadt, Germany. Carine Savarin is an employee of Merck Sant\u00e9 S.A.S., Lyon, France, an affiliate of Merck KGaA. Julie Korich is an employee of EMD Serono, Inc., Boston, MA, USA, an affiliate of Merck KGaA. Luca Bonsignore is an employee of Merck (Schweiz) AG, Zug, Switzerland, an affiliate of Merck KGaA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This review article is based on previously conducted studies and the clinical expertise of the authors in treating patients with relapsing multiple sclerosis. No new clinical studies were performed by the authors. No patient-specific efficacy or safety data were reported; therefore, institutional review board (IRB)\/ethics approval was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}